calcium polystyrene sulfonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4871	37286-92-3

Description:

Molecule

Description

Synonyms:

calcium polystyrene sulfonate
calcium polystyrene sulphonate
calcium polystyrenesulfonate
kalimate

Molecular weight:
Formula: (C16H14CaO6S2)n
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
45	g	O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	63.64	36.49	30	911	75631	50528552
Hyperkalaemia	49.60	36.49	22	919	48067	50556116
Cardiac failure	40.02	36.49	22	919	76018	50528165

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Crystal deposit intestine	72.27	29.30	11	1656	90	29572770
Hyperkalaemia	71.84	29.30	44	1623	61348	29511512
Renal impairment	41.01	29.30	35	1632	81298	29491562

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	111.47	28.56	64	2785	101065	64394818
Renal impairment	92.06	28.56	63	2786	134954	64360929
Crystal deposit intestine	74.08	28.56	12	2837	197	64495686
Cardiac failure	52.95	28.56	45	2804	132328	64363555
Hepatic function abnormal	46.07	28.56	31	2818	64282	64431601
Shunt stenosis	43.64	28.56	10	2839	1057	64494826
Anaemia	37.65	28.56	63	2786	378617	64117266
Interstitial lung disease	36.55	28.56	32	2817	97700	64398183
Chronic kidney disease	34.64	28.56	25	2824	57894	64437989

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AE01	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
MeSH PA	D002411	Cation Exchange Resins
MeSH PA	D002614	Chelating Agents
MeSH PA	D007475	Ion Exchange Resins
MeSH PA	D064449	Sequestering Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperkalemia	indication	14140009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
HUI2S00793	UNII
D03270	KEGG_DRUG
C0108139	UMLSCUI
CHEBI:53277	CHEBI
CHEMBL2109033	ChEMBL_ID
169893	PUBCHEM_CID
C003321	MESH_SUPPLEMENTAL_RECORD_UI
28210-41-5	SECONDARY_CAS_RN
75905	PUBCHEM_CID
DB01344	DRUGBANK_ID
1546437	RXNORM
003509	NDDF
006664	NDDF
1002242008	SNOMEDCT_US
395788004	SNOMEDCT_US
710808009	SNOMEDCT_US
C0137904	UMLSCUI
CHEMBL1201484	ChEMBL_ID
8324	INN_ID
ZSL2FB6GXN	UNII

Pharmaceutical products:

None